Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992332 | 0.87 | SRD5A2 (0.41) | NR1I3GRIN1GRIN2BSRD5A2AKR1B10 | |
| SCHEMBL17065133 | 0.83 | AKR1B10 (0.58) | GRIN1GRIN2BSRD5A2AKR1B10AKR1B1 | |
| SCHEMBL3361092 | 0.82 | SRD5A2 (0.40) | SRD5A2AKR1B10AKR1B1GPBAR1 | |
| SCHEMBL8964931 | 0.82 | CYP19A1 (0.49) | SRD5A2AKR1B10AKR1B1GPBAR1 | |
| SCHEMBL8964927 | 0.82 | CYP19A1 (0.49) | SRD5A2AKR1B10AKR1B1GPBAR1 | |
| SCHEMBL9706991 | 0.81 | CYP17A1 (0.46) | SRD5A2AKR1B10AKR1B1GPBAR1 | |
| SCHEMBL324889 | 0.81 | NR1I3 (0.53) | NR1I3GRIN1GRIN2BMBOAT4CDK5 | |
| SCHEMBL9293470 | 0.79 | GRIN1 (0.50) | NR1I3GRIN1GRIN2BMBOAT4CDK5 | |
| SCHEMBL7804314 | 0.79 | NR1I3 (0.46) | NR1I3GRIN1GRIN2BMBOAT4CDK5 | |
| SCHEMBL9348284 | 0.78 | NR1I3 (0.48) | NR1I3GRIN1GRIN2BMBOAT4CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534298-A2 | NOVEL ANTICHOLESTEROL COMPOSITIONS AND METHOD FOR USING SAME | Anagen Therapeutics, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004001002-A2 | NOVEL ANTICHOLESTEROL COMPOSITIONS AND METHOD FOR USING SAME | ANAGEN THERAPEUTICS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030153541-A1 | Novel anticholesterol compositions and method for using same | ANAGEN THERAPEUTICS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20020152479-A1 | Car modulators: screening and treatment of hypercholesterolemia | ARROW ACQUISITION, LLC | 2002-10-17 | — | — | US | disclosed |
| WO-2001051045-A2 | MODULATORS OF THE CONSTITUTIVE ADROSTANE RECEPTOR (CAR): SCREENING AND TREATMENT OF HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-1996036230-A1 | MODULATORS FOR NEW MEMBERS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020152479-A1 | Car modulators: screening and treatment of hypercholesterolemia | LDLR, LCAT, CETP | NR1I3 32/4885GRIN1 2676/4885GRIN2B 3874/4885 |
| US-20030153541-A1 | Novel anticholesterol compositions and method for using same | CYP46A1, NR1H4, NR1H3 | NR1I3 67/4885GRIN1 2662/4885GRIN2B 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.